Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.
Cardiff Lexington Corporation (OTCQB: CDIX) is a healthcare holding company focused on acquiring and building middle-market niche health care clinics in Orthopedics, Spine Care, and Pain Management. This news page aggregates company-issued updates and market-facing announcements that reflect how Cardiff Lexington and its Nova Ortho and Spine subsidiary are progressing operationally, financially, and strategically.
Readers can find earnings releases detailing quarterly and year-to-date financial performance, including revenue trends, gross profit, operating income, net loss, and non-GAAP measures such as adjusted EBITDA. These releases often discuss the impact of one-time non-cash adjustments, changes in interest expense related to the company’s line of credit, and enhancements to internal controls over financial reporting.
The news flow also includes corporate governance and leadership updates, such as the planned retirement of long-serving Chairman Daniel Thompson and the appointment of Chief Executive Officer Alex Cunningham as Chairman of the Board. Cardiff Lexington uses press releases to explain these changes and to describe how its leadership team is shaping strategy and operations.
Investors following CDIX can track capital markets developments through announcements about the company’s uplisting strategy, including the 1-for-3 reverse stock split intended to support Nasdaq Capital Market listing requirements and the filing of a Form S-1 registration statement. Additional releases highlight advisory relationships, such as the engagement of Greentree Financial Group to assist with governance, financial reporting, and public markets compliance.
Operationally, Cardiff Lexington’s news coverage features updates from Nova Ortho and Spine, including expansion into underserved and rural areas of Florida and the performance of procedures at partner hospitals. By reviewing this news feed, investors and observers can monitor Cardiff Lexington’s financial reporting schedule, conference call announcements, and ongoing efforts to grow its orthopedic, spine care, and pain management platform.
Cardiff Lexington (OTCQB:CDIX) announced a 1-for-3 reverse stock split effective 12:01 a.m. ET on January 12, 2026. Every three pre-split shares were combined into one post-split share; fractional shares were not issued and were rounded up to the nearest whole share. The par value remained $0.001 and unchanged. The company’s common stock will trade on a split-adjusted basis on the OTCQB today, and the ticker will temporarily change to CDIXD for 20 trading days including the effective date. The stated purpose is to support compliance with Nasdaq Capital Market minimum bid price requirements. Post-split CUSIP is 14146R700.
Cardiff Lexington (OTCQB: CDIX) announced that long-serving Chairman Daniel Thompson will retire effective December 31, 2025 after 25 years of service. Alex Cunningham, President and Chief Executive Officer, will succeed Thompson as Chairman and assume the additional role immediately upon retirement.
The release says the company is positioned for further growth, highlights expansion of its operating subsidiary Nova Ortho and Spine in 2025, and cites a targeted plan to uplist the stock to a major US exchange to broaden investor visibility.
Cardiff Lexington (OTCQB:CDIX) announced that its subsidiary Nova Ortho and Spine performed first procedures on December 11, 2025 at Doctor's Memorial Hospital in Perry, Florida.
The move targets Taylor County, described as severely underserved with poor health outcomes and a high provider-to-patient ratio; Cardiff Lexington said the visit brings pain management, orthopedic, and spine surgical services to the local community and signals intent to expand into additional rural Florida areas.
Cardiff Lexington (OTCQB: CDIX) announced on November 20, 2025 that it entered an advisory agreement with Greentree Financial Group to support its uplisting strategy and strengthen financial reporting and governance.
Greentree will assist with the company’s audit process, S-1 filing, SEC and exchange comment responses, governance initiatives, and coordination with attorneys, CPAs, and transfer agents. Management described the engagement as a step toward uplisting to a major U.S. exchange and improving public markets compliance.
Cardiff Lexington (OTCQB:CDIX) reported third quarter results for the period ended September 30, 2025, showing substantial revenue and margin improvement versus the prior-year quarter.
- Total revenue rose 125.6% to $3.1 million (3Q24 included a one-time $1.7M accounting charge).
- Gross profit increased 437.8% to $1.9 million (62.4% margin).
- Income from continuing operations improved to $643,000 (21.0% of revenue).
- Non-GAAP adjusted EBITDA for Q3 was $663,000; year-to-date adjusted EBITDA was $1.9 million.
- Cash totaled $232,000 and total assets were $27.6 million.
Cardiff Lexington (OTCQB:CDIX) will release third quarter 2025 financial and operating results for the period ended September 30, 2025 and host a conference call on Friday, November 14, 2025 at 9:00 AM ET. The results will be released prior to the call.
Participants may join by dialing (888) 506-0062 (U.S.) or (973) 528-0011 (international) and using access code 223050. The call and slide deck will be webcast at https://www.webcaster5.com/Webcast/Page/3131/53160 and via the company Investor Relations page https://investor.cardifflexington.com/overview/default.aspx. A replay will be available one hour after the call through Friday, November 28, 2025 by dialing (877) 481-4010 (U.S.) or (919) 882-2331 (international) using access code 53160.
Cardiff Lexington (OTCQB:CDIX) reported strong Q2 2025 financial results, with total revenue increasing 89.5% to $2.8 million compared to Q2 2024. The company achieved significant improvements across key metrics, including a 149.8% increase in gross profit to $1.7 million and a 482.3% rise in income from continuing operations to $610,000.
Operating through 12 Nova Ortho & Spine locations in Florida and Georgia, the company demonstrated robust operational performance with gross margins reaching 60.8%. However, net loss widened to $1.2 million, primarily due to increased interest expenses of $1.8 million related to the company's line of credit. Non-GAAP adjusted EBITDA improved to $708,000 compared to a loss of $76,000 in Q2 2024.
Cardiff Lexington (OTCQB:CDIX) has scheduled its Q2 2025 financial results conference call for Tuesday, August 26, 2025, at 9:00 am ET. The company will release its financial results for the quarter ended June 30, 2025, before the call.
Investors can join via phone by dialing (888) 506-0062 (US) or (973) 528-0011 (International) using access code 861636. The call and slide deck will be available via webcast, and a replay will be accessible until September 9, 2025.
Cardiff Lexington (OTCQB:CDIX) has announced the postponement of its second quarter 2025 earnings release and investor conference call. The company has not provided a specific new date for the release of its Q2 2025 results but stated it will announce the timing through a press release when determined.
Cardiff Lexington (OTCQB:CDIX) has scheduled an investor conference call to discuss its Q2 2025 financial results on Tuesday, August 12, 2025, at 5:00 pm ET. The company will release its financial and operating results for the quarter ended June 30, 2025, before the call.
Investors can join via phone by dialing (877) 545-0523 (US) or (973) 528-0016 (International) using access code 674660. The call and slide deck will be available via webcast, with replay access until August 26, 2025.
FAQ
What is the current stock price of Cardiff Lexingto (CDIX)?
What is the market cap of Cardiff Lexingto (CDIX)?
